
DERM Stock Forecast & Price Target
DERM Analyst Ratings
Bulls say
Journey Medical Corp demonstrates a positive growth trajectory characterized by a significant expansion in payer access, increasing from approximately 30% of commercial lives in May to about 65% by July, representing coverage for over 100 million lives. Additionally, prescriber adoption has shown remarkable growth, with the number of prescribers rising from around 660 in the first quarter to more than 1,800 by the second quarter, indicating strong demand for its products. Furthermore, the established brand value of Journey's products, particularly Accutane, enhances consumer retention and supports the company's ability to maintain market share amid competitive pressures.
Bears say
Journey Medical Corp is experiencing a decline in prescription volume, with Accutane prescriptions dropping significantly from 93,000 in the first quarter of 2024 to 66,000 in the same period of 2025, signaling potential challenges in market demand. The company faces several key risks that could hinder financial performance, including competitive pressures from both branded and generic alternatives, slow uptake of new products like Emrosi, and potential reimbursement issues. Additionally, concerns regarding capital requirements resulting from cash burn exceeding projections, along with execution risks in scaling sales efforts, contribute to a fundamentally negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Journey Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
DERM Analyst Forecast & Price Prediction
Start investing in DERM
Order type
Buy in
Order amount
Est. shares
0 shares